KLRS Company Profile and Key Details

Kalaris Therapeutics Inc has 18.70 million shares outstanding. The public float is 4.31 million shares, elevated short interest at 2.34% of float. This equals 110.79 thousand shares. The short ratio is 2.22 days. Institutional investors hold 85.4% of the float. Insiders own 8.81%. Over the past six months, insider transactions show balanced activity. They sold 1.92 thousand shares across 1 transactions.

KLRS has shown sold momentum, gaining 10.97% over the past week and 111.88% over the past quarter, though year-to-date performance is up 16.23%. Short-term trend indicators are bearishly aligned (SMA20 10.81%, SMA50 12.87%, SMA200 96.23%). The stock’s 14-day RSI is 57.28 (neutral), while the ATR of 0.97 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.14% below its high and over 393.46% above its low. Average 10-day trading volume of 1.52 million shares is significantly above the 3-month average of 276.46 thousand, indicating heightened recent market interest.

Kalaris Therapeutics Inc generated EPS of -$7.40 over the past year. Five-year average earnings growth is -6.86%. Wall Street analysts project EPS growth of 48.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $14.00. The high target offers 514.25% upside. The low target suggests 243.98% downside. The mean target is $19.67. This offers 383.29% upside. Kalaris Therapeutics Inc earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -11.54%. The prior quarter beat by -21.43%. Over the last six quarters, Apple has recorded several small beats. These include 31.84% in March 07, 2025.

Kalaris Therapeutics Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.33. This means the shares are trading below this model’s fair value.

Kalaris Therapeutics Inc (NASDAQ:KLRS) closed at $4.07 USD, gaining $0.03 (0.74%) from the previous close of $4.04. The stock is currently mid-range between its 52-week high and low $2.14 and $11.88. With a market capitalization of about $76.12 million, Kalaris Therapeutics Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 267.10 thousand shares, volume is running light vs its 52-week average. Headquartered in Berkeley Heights, NJ, Kalaris Therapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew Oxtoby, the company employs approximately 20 people and listed since July 30, 2020. Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.

Kalaris Therapeutics Inc trades at a P/E ratio of -1.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.4 suggesting the stock is closer to book value. The P/FCF stands at -1.54, also above market averages.

Our AI price prediction model suggests that Kalaris Therapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.72%, with price expected at $4.14 by August 05, 2026, within a range of $3.88 to $4.40 3-Month Outlook: Projected fall of -5.16%, reaching $3.86 by October 20, 2026, with a range of $3.52 to $4.15. 1-Year Outlook: Projected gain of 81.08%, with price at $7.37 by July 22, 2027, within a range of $7.08 to $7.66.

Kalaris Therapeutics Inc (NASDAQ:KLRS) shares are up 16.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kalaris Therapeutics Inc trading at a premium to the broader market with a P/E of -1.88. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $19.67, suggesting 383.29% upside. Our AI forecast model points to short-term strength (1.72% over two weeks), a medium-term fall (-5.16% over three months), and a longer-term gain (81.08% over one year), with expected trading ranges indicating moderate volatility.